Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 3/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959809 | 1.00 | SLC15A2 (0.50) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL1959812 | 1.00 | SLC15A2 (0.50) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL4590038 | 0.99 | SLC15A2 (0.49) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL4589288 | 0.99 | SLC15A2 (0.49) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL2811601 | 0.99 | SLC15A2 (0.49) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| Hydrochloric Acid SCHEMBL7805623 | 0.99 | SLC15A2 (0.49) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL2247594 | 0.99 | SLC15A2 (0.49) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| Acetic Acid SCHEMBL9411947 | 0.98 | SLC15A2 (0.48) | SLC15A2GHSRNOD1ECE1FOLH1 | |
| SCHEMBL8000316 | 0.97 | SLC15A2 (0.47) | SLC15A2GHSRECE1ERAP2ERAP1 | |
| SCHEMBL8000305 | 0.97 | SLC15A2 (0.47) | SLC15A2GHSRECE1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725495-A2 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12220599-B2 | Wearable phototherapy apparatus with anti-viral and other effects | SOLETLUNA HOLDINGS, INC. (US) | 2025-02-11 | — | — | US | claimed |
| EP-4082607-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2022-11-02 | — | — | EP | claimed |
| US-20220096861-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | SOLETLUNA HOLDINGS, INC. (US) | 2022-03-31 | — | — | US | claimed |
| US-10898724-B2 | Wearable phototherapy apparatus with anti-viral and other effects | SOLETLUNA HOLDINGS, INC. (US) | 2021-01-26 | — | — | US | claimed |
| WO-2020251816-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | SOLETLUNA HOLDINGS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| US-20200391045-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | SOLETLUNA HOLDINGS, INC., (US) | 2020-12-17 | — | — | US | claimed |
| EP-3750594-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2020-12-16 | — | — | EP | claimed |
| US-10716953-B1 | Wearable phototherapy apparatus | SOLETLUNA HOLDINGS, INC. (US) | 2020-07-21 | — | — | US | claimed |
| EP-4725495-A2 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4082607-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3750594-A1 | WEARABLE PHOTOTHERAPY APPARATUS WITH ANTI-VIRAL AND OTHER EFFECTS | Soletluna Holdings, Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10716953-B1 | Wearable phototherapy apparatus | SOLETLUNA HOLDINGS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| EP-0522004-A1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0514460-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| US-5164367-A | Complexes with peptides | PROCYTE CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-5118665-A | Enhance or restore resistance of mammals to damage caused by release of reactive oxygen species | PROCYTE CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| WO-1991014437-A2 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| WO-1991012267-A1 | ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF | PROCYTE CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | SLC15A2 1553/4885GHSR 854/4885NOD1 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.